Document is current
Any future updates will be listed below
-
Authors
Adams, Jamie L. https://orcid.org/0000-0002-1170-6688
Kangarloo, Tairmae
Tracey, Brian https://orcid.org/0000-0003-1526-6349
O’Donnell, Patricio https://orcid.org/0000-0001-7788-624X
Volfson, Dmitri
Latzman, Robert D. https://orcid.org/0000-0002-1175-8090
Zach, Neta
Alexander, Robert
Bergethon, Peter
Cosman, Joshua
Anderson, David
Best, Allen https://orcid.org/0000-0001-9363-4173
Severson, Joan
Kostrzebski, Melissa A.
Auinger, Peggy
Wilmot, Peter
Pohlson, Yvonne
Waddell, Emma https://orcid.org/0000-0002-8863-0335
Jensen-Roberts, Stella
Gong, Yishu https://orcid.org/0000-0002-7777-6363
Kilambi, Krishna Praneeth https://orcid.org/0000-0003-4848-2611
Herrero, Teresa Ruiz
Ray Dorsey, E. https://orcid.org/0000-0002-5140-1248
,
Adams, Jamie L.
Tarolli, Christopher
Waddell, Emma
Jensen-Roberts, Stella
Soto, Julia
Hogarth, Penelope
Wahedi, Mastura
Wakeman, Katrina
Espay, Alberto J.
Brown, Julia
Wurzelbacher, Christina
Gunzler, Steven A.
Khawam, Elisar
Kilbane, Camilla
Spindler, Meredith
Engeland, Megan
Tarakad, Arjun
Barrett, Matthew J.
Cloud, Leslie J.
Norris, Virginia
Mari, Zoltan
Wyant, Kara J.
Chou, Kelvin
Stovall, Angela
Poon, Cynthia
Simuni, Tanya
Tingling, Kyle
Luthra, Nijee
Tanner, Caroline
Yilmaz, Eda
Romero, Danilo
Thomas, Karen
Matson, Leslie
Richardson, Lisa
Fullard, Michelle
Feuerstein, Jeanne
Shelton, Erika
Shprecher, David
Callan, Michael
Feigin, Andrew
Romano, Caitlin
Romain, Martina
Shum, Michelle
Botting, Erica
Harrell, Leigh
Rocha, Claudia
Ramdhani, Ritesh
Gardner, Joshua
Parker, Ginger
Ross, Victoria
Stephen, Steve
Fisher, Katherine
Edgerton, Jeremy
Cedarbaum, Jesse
Rubens, Robert
Padmanabhan, Jaya
Stephenson, Diane
Severson, Brian
Merickel, Michael
Amato, Daniel Jackson
Carroll, Thomas
- License Information
-
More Information
Article History
Received: 18 November 2022
Accepted: 27 February 2023
First Online: 17 April 2023
Competing interests
: Dr. Adams has received compensation for consulting services from VisualDx and the Huntington Study Group; and research support from Biogen, Biosensics, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, NeuroNext Network, and Safra Foundation. Ms. Tairmae Kangarloo, Dr. Brian Tracey, Dr. Dmitri Volfson, Dr. Neta Zach, and Dr. Robert Latzman are employees of and own stock in Takeda Pharmaceuticals, Inc. Dr. Josh Cosman is an employee of and owns stock in AbbVie Pharmaceuticals. Dr. Jeremey Edgerton, Dr. Krishna Praneeth Kilambi, and Katherine Fisher are employees of and own stock in Biogen Inc. Dr. Peter R. Bergethon was an employee of Biogen during a portion of this study. He has no conflicts or interests at the present time. Dr. Dorsey has received compensation for consulting services from Abbott, Abbvie, Acadia, Acorda, Bial-Biotech Investments, Inc., Biogen, Boehringer Ingelheim, California Pacific Medical Center, Caraway Therapeutics, Curasen Therapeutics, Denali Therapeutics, Eli Lilly, Genentech/Roche, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, Karger Publications, LifeSciences Consultants, MCM Education, Mediflix, Medopad, Medrhythms, Merck, Michael J. Fox Foundation, NACCME, Neurocrine, NeuroDerm, NIH, Novartis, Origent Data Sciences, Otsuka, Physician’s Education Resource, Praxis, PRIME Education, Roach, Brown, McCarthy & Gruber, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Theravance, Voyager and WebMD; research support from Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation, and Wave Life Sciences; editorial services for Karger Publications; stock in Included Health and in Mediflix, and ownership interests in SemCap. Ms. Kostrzebski holds stock in Apple, Inc. Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Bexion, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), Avion Pharmaceuticals, and Herantis Pharma; personal compensation as honoraria for speakership for Avion; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics (a biotech start-up developing nonaggregating peptide analogues as replacement therapies for neurodegenerative diseases) and is co-owner of a patent that covers synthetic soluble nonaggregating peptide analogues as replacement treatments in proteinopathies. Dr. Spindler has received compensation for consulting services from Medtronic, and clinical trial funding from Abbvie, Abbott, US WorldMeds, Praxis, and Takeda. Dr. Wyant receives research funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke NeuroNEXT Network, Eli Lilly, and the Farmer Family Foundation. She also receives royalties from UpToDate. Joan Severson, Allen Best, David Anderson, Michael Merickel, Daniel Jackson Amato, and Brian Severson are employees of Clinical Ink, who acquired the BrainBaseline Platform in 2021 from Digital Artefacts. Joan Severson and Allen Best have financial interests in Clinical Ink.
